Investment
Features
FeesSafety
Academy
More
Pluang+

Compare F.N.B. Corporation Common Stock (FNB) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

F.N.B. Corporation Common StockTrade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

F.N.B. Corporation Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? F.N.B. Corporation Common Stock trades at $16.96 (market cap $6.07B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: F.N.B. Corporation Common Stock is far larger — about 3.4× Vir Biotechnology Inc. Common Stock's market cap, and F.N.B. Corporation Common Stock pays a 3.05% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

FNBVIR
Market Cap
$6.07B$1.80B
Volume
5,600,6091,782,836
Sector
FinancialsHealth
52-Week High
$19.49$11.78
52-Week Low
$14.65$5.12
Typical Hold Time
0 Days0 Days
Enterprise Value
$10.61B$1.36B
Dividend Yield
3.05%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

F.N.B. Corporation Common Stock

FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.

The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FNB
100% Buy0% Sell
Avg holding period · 0 Days
VIR
51% Buy49% Sell
Avg holding period · 0 Days

About F.N.B. Corporation Common Stock

F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.

Read more on FNB →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →